全文获取类型
收费全文 | 134456篇 |
免费 | 13941篇 |
国内免费 | 6630篇 |
专业分类
耳鼻咽喉 | 1402篇 |
儿科学 | 2135篇 |
妇产科学 | 3122篇 |
基础医学 | 13510篇 |
口腔科学 | 2710篇 |
临床医学 | 17026篇 |
内科学 | 21947篇 |
皮肤病学 | 2001篇 |
神经病学 | 6968篇 |
特种医学 | 4380篇 |
外国民族医学 | 40篇 |
外科学 | 15408篇 |
综合类 | 19308篇 |
现状与发展 | 20篇 |
一般理论 | 18篇 |
预防医学 | 9937篇 |
眼科学 | 3952篇 |
药学 | 13500篇 |
114篇 | |
中国医学 | 6538篇 |
肿瘤学 | 10991篇 |
出版年
2024年 | 429篇 |
2023年 | 2376篇 |
2022年 | 4079篇 |
2021年 | 5665篇 |
2020年 | 4419篇 |
2019年 | 3800篇 |
2018年 | 4565篇 |
2017年 | 4400篇 |
2016年 | 3907篇 |
2015年 | 5780篇 |
2014年 | 7470篇 |
2013年 | 7594篇 |
2012年 | 10391篇 |
2011年 | 11106篇 |
2010年 | 7926篇 |
2009年 | 6759篇 |
2008年 | 8001篇 |
2007年 | 7815篇 |
2006年 | 7460篇 |
2005年 | 6763篇 |
2004年 | 4887篇 |
2003年 | 4434篇 |
2002年 | 3691篇 |
2001年 | 3186篇 |
2000年 | 2888篇 |
1999年 | 2711篇 |
1998年 | 1392篇 |
1997年 | 1308篇 |
1996年 | 1043篇 |
1995年 | 1007篇 |
1994年 | 923篇 |
1993年 | 536篇 |
1992年 | 926篇 |
1991年 | 833篇 |
1990年 | 687篇 |
1989年 | 586篇 |
1988年 | 545篇 |
1987年 | 460篇 |
1986年 | 365篇 |
1985年 | 288篇 |
1984年 | 188篇 |
1983年 | 174篇 |
1982年 | 107篇 |
1981年 | 102篇 |
1979年 | 143篇 |
1978年 | 114篇 |
1977年 | 86篇 |
1974年 | 95篇 |
1973年 | 74篇 |
1972年 | 89篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
3.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
4.
Depeng Meng Yichen Meng Bingyang Li Guigang Zeng Bin Zhang Chunlin Hou Haodong Lin Yueping Ouyang 《Journal of orthopaedic science》2021,26(3):409-414
BackgroundComminuted patellar fractures are not rare, and the ideal treatment method remains controversial. The present study was conducted to evaluate effects and compare complications of two different methods used to treat comminuted patellar fractures.MethodsFrom March 2010 to August 2016, 102 cases of 34-C2 or 34-C3 comminuted patellar fractures were treated at our hospital, wherein patients received two different treatments: titanium cable tension band with cerclage method (group A) and intrafragmentary screws with X-shaped plating technique (group B). At follow-ups, articular step-off, range of motion (ROM), Lysholm scores, time of union, and complications were recorded and analyzed. Radiographic and clinical data as well as rate of complications were statistically analyzed.ResultsIn total, 87 patients were included in the final analysis (n = 47 in group A and n = 40 in group B). No significant differences were noted in terms of cost of implant, age, gender, rate of 34-C3 fractures, rate of layered inferior pole fractures, postoperative articular step-off and union time. At 2-year follow-up, average Lysholm scores, ROM and rate of complications were (89.0 ± 4.5), (122°±12°) and (27.7%) in group A and (90.2 ± 3.9), (124°±11°) and (17.5%) in group B, respectively, with no significant differences (p > 0.05). The mean time of surgery in group B was shorter than that in group A with significant difference (p < 0.05).ConclusionsTreatment using the intrafragmentary screws and plate method for amenable comminuted patellar fractures achieved similar complication rate and favorable functional outcomes at the 2-year follow-up, which was comparable to the titanium cable tension band with cerclage method. Thus, the intrafragmentary screws and plate method is effective, safe and convenient for 34-C2/C3 comminuted patellar fractures, especially appropriate for patients with layered fragments. 相似文献
5.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
6.
7.
Autoimmune comorbid diseases associated with lichen planus: a nationwide case–control study
下载免费PDF全文
![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
8.
9.
目的 评价调整光学切削直径及Kappa角后对准分子激光原位角膜磨镶术(laser in situ keratomileusis,LASIK)后效果的影响。方法 选取2017年1月至12月在我院行LASIK手术的高度近视患者313例(626眼),根据切削直径分成两组,试验组157例314眼,切削直径设定为6.0 mm,对照组156例312眼,切削直径设定为6.5 mm。试验组患者激光切削前修正Kappa角,对照组不做修正。患者术前进行裸眼视力、主视眼确定、验光、眼压、暗室下瞳孔直径、泪液分泌试验、裂隙灯、散瞳验光、眼底检查、pentacam测量角膜厚度、角膜地形图测量角膜前后表面及Kappa角等检查。术后1 d、1周、1个月随访,并检查裸眼视力、角膜厚度、波前像差及夜间视力、光晕、眩光等情况。比较两组患者角膜厚度变化、手术所用时间以及两组患者术后的高阶像差的差异。结果 试验组与对照组患者年龄分别为18~44(24.19±5.33)岁、18~42(25.08±4.91)岁,屈光度分别为(-7.47±1.04)D、(-7.61±1.12)D。两组年龄、屈光度比较差异均无统计学意义(均为P>0.05)。试验组与对照组患者术前Kappa角分别为,X轴:(210±40)μm、(200±30)μm,Y轴:(190±30)μm、(220±40)μm,差异无统计学意义(P=0.210)。两组手术前后的角膜厚度及术后角膜基质床的厚度差异均无统计学意义(均为P>0.05)。试验组与对照组的手术时间分别为(15.56±1.89)s和(20.83±3.03)s,差异有统计学意义(P=0.000)。试验组的总高阶像差和垂直慧差的变化均明显低于对照组(均为 P<0.01),但两组间的水平慧差差异无统计学意义(P>0.05),对照组的球差低于试验组(P<0.01)。结论 LASIK手术中科学合理地调整Kappa角可有助于提高患者术后的视觉质量。 相似文献